RXi Pharmaceuticals Corporation (Worcester, MA) and
EyeGate Pharma (Waltham, MA) have announced a partnership
to deliver ocular RNAi therapeutics to treat retinal
disorders. Each party will contribute technology, expertise,
and resources to the collabo…
The Ozurdex dexamethasone intravitreal implant
(Allergan, Inc.) effectively reduced DME and improved
visual acuity in vitrectomized eyes, according to data presented
by Leonard Feiner, MD, at the ASRS meeting.1
In a 6-month, prospective, multicenter, o…
A single injection of microplasmin (ThromboGenics
NV) for the nonsurgical treatment of vitreomacular adhesion
(VMA) performed well in two phase 3 trials, referred
to as MIVI-TRUST, according to presenters at the ASRS.
Both trials were multicenter, rand…
R-Tech Ueno Ltd. (Tokyo, Japan) announced it has
completed a phase 2 clinical trial of 0.15% UF-021 isopropyl
unoprostone (Ocuseva), which is under development
as a treatment for retinitis pigmentosa. The
trial investigated the possibility of improving…
Novartis AG (Basel, Switzerland) announced that it
has completed the acquisition of a majority stake in
Alcon, Inc. (Huenenberg, Switzerland), even as Alcon’s
minority shareholders continue to lobby for a higher
value on the remaining shares.
In the …
Children who wear contact lenses have better visionrelated
quality of life than children who wear eyeglasses,
according to a study published in Optometry and Vision
Science.1
A total of 484 nearsighted children aged 8 to 11 years
were randomly assigned…